间充质干细胞在肝硬化治疗中的研究进展  

Research progress on mesenchymal stem cells in the treatment of liver cirrhosis

作　　者：张邸涵婧 陆伦根[1] ZHANGDI Han-jing;LU Lun-gen(Department of Gastroenterology,Shanghai GeneralHospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China)

机构地区：[1]上海交通大学医学院附属第一人民医院消化内科,上海200080

出　　处：《内科急危重症杂志》2024年第1期4-7,共4页Journal of Critical Care In Internal Medicine

摘　　要：肝硬化是各种慢性肝病的终末期,主要由活化的肝星状细胞产生胶原并累积在细胞外基质形成假小叶从而导致肝纤维化和肝硬化。间充质干细胞具有多能分化的能力,可参与多种疾病的细胞治疗。近年来,越来越多的实验研究证明了间充质干细胞可用于肝硬化的治疗。本文将对间充质干细胞治疗肝硬化的研究进展进行总结及展望。Liver cirrhosis is the end stage of chronic liver disease.Collagen is produced by activated hepatic stellate cells and accumulates in the extracellular matrix to form pseudolobules,leading to liver fibrosis and cirrhosis.Mesenchymal stem cells(MSCs) have the ability of multipotent differentiation and can be involved in cell therapy for a variety of diseases.In recent years,more and more experimental studies have proved that mesenchymal stem cells can participate in the treatment of liver cirrhosis.This article summarizes the research progress and prospect of mesenchymal stem cells in the treatment of liver cirrhosis.

关 键 词：间充质干细胞 肝硬化 治疗 

分 类 号：R575.2[医药卫生—消化系统]